Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — Investor Presentation (November 2022)
28 slides from Par Drugs And Chemicals's investor presentation, Nov 23, 2022
Slide 1: Cover letter to National Stock Exchange of India
PAR/CS/NSE/2022-23/47 To, Date: 23/11/2022 The Manager Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai- 400 051 Maharashtra Symbol - PAR, ISIN: INE04LG01015 Subject: Investors Presentation Ref.: Regulation 30 read wi
Slide 2: Investor Presentation | November 2022
Investor Presentation| November 2022
Slide 3: Executive Summary
2 Executive Summary Overview • Incorporated in 1999, Par Drugs and Chemicals Limited hereinafter referred to as “Company” or “PDCL” is engaged in the development and manufacture of Active Pharma Ingredients (“APIs”) and Fine Chemicals for the domestic market as well as for exports to international m
Slide 4: Company Overview
Company Overview
Slide 5: Company Overview
4 Company Overview Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development 209 and manufacturing of APIs. 194 218 • The Company today manufactures 25 different products and all
Slide 6: Board of Directors
5 Board of Directors Falgun Vallabhbhai Savani Pravin Manjibhai Bhayani Managing Director Independent Director • Holds Bachelor’s degree in Pharmacy from B. K. Modi Government Pharmacy College, Rajkot affiliated with Saurashtra University. • Has 21 years of experience in the API Industry and is play
Slide 7: Geographical Presence
6 Geographical Presence Canada United Kingdom Germany Iran Syria Japan Jordan China PRP South Korea India Hong Kong UAE Bangladesh Thailand Sri Lanka Indonesia Colombia 13+ 40+ Manufacturing Facility Bhavnagar, Gujarat having a capacity of 9,700 MTPA. Agents Globally Dealers in India
Slide 8: Key Milestones
7 Key Milestones Mr. V. J. Savani established in the year 1982 in the name of Par Inorganics, later Par Drugs and Chemicals was incorporated in the year 1999. • Brownfield expansion of 1,400 MTPA • Commissioning of Fine Chemical for the Japanese market • Established 2nd • The equity shares of the ma
Slide 9: Research & Development
8 Research & Development • Company’s focus is on developing non-infringing processes and achieving process improvements and production cost efficiencies. • The main focus will be to expand the ability to penetrate different applications of current molecules with modified physical and chemical struct
Slide 10: Manufacturing Facility
9 Manufacturing Facility Manufacturing Facility - Chitra, Bhavnagar, Gujarat There are four Manufacturing Blocks are for different products having a capacity of 9,700 MTPA. Block 1 – APIs Block 2 - Magnesium Hydroxide Block 3 - Fine Chemicals Block 4 – APIs/ Fine Chemicals
Slide 11: Manufacturing Process
10 Manufacturing Process Procurement of Raw Quality Control and Material Reaction Filtration Drying Sampling Packaging Procurement of Chemical reaction After the reaction, Excess water from The sampling is The material is sent magnesium takes place in a the slurry has to be the product is done for t
Slide 12: Business Overview
Business Overview
Slide 13: Key Strengths
12 Key Strengths Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 15 APIs and 10 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is operating both in domestic and e
Slide 14: Business Overview
13 Business Overview The company is one of the largest manufacturer in Magnesium Hydroxide, Sucralfate and Magnesium Trisilate in India. API (56%) (57%) Fine Fine Chemicals Chemicals (43%) (42%) Magnesium Hydroxide Magnesium Oxide USP Precipitated Precipitated Silica Silica Sodium Sodium Aluminium A
Slide 15: Business Verticals
14 Business Verticals API • PDCL currently produces the entire range of Antacid Molecules available in the market. • Antacids are medication that neutralizes stomach acid to cut down on heartburn, sour stomach, acid indigestion, and stomach upset, symptoms of Gastroesophageal Reflux Disease (GERD al
Slide 16: APIs and their Applications
15 APIs and their Applications Magnesium Hydroxide Magnesium Aluminosilicate-USP Magnesium Aluminium Hydrate • Widely used as an Antacid in many Formulations • Used as an Antacid Raw material in a specific • Used as an Antacid Raw material in a specific helping reduce stomach acid antacid Formulatio
Slide 17: Fine Chemicals and their Applications
16 Fine Chemicals and their Applications Fine chemicals are chemical substances prepared to a very high degree of purity. They can be used in different industries. These chemicals are used for special applications by manufacturing firms that make the following products: Pharmaceuticals, paints, petr
Slide 18: Future Strategy
17 Future Strategy Expand the product portfolio: Seek to leverage the R&D capabilities to expand PDCL’s Product Portfolio and thus penetrate the different segments of application and value added products. This will ultimately increase the profitability by value addition. Exploring new geographical a
Slide 19: Industrial Overview
Industrial Overview
Slide 20: API Industry
19 API Industry Global API Market Size Global Antacid Market Size (USD Bn) (USD Bn) • The global active pharmaceutical ingredients market was prized by USD 205.60 Bn 2020. It is estimated to witness a 6.6% CAGR from 2021 to 2028. CAGR 6.6% CAGR 3.9% • The global antacids market size was valued at US
Slide 21: Fine Chemical Industry
20 Fine Chemical Industry • The global Fine Chemicals market size is projected to reach USD 2,78,510 Mn by 2027, from USD 1,72,510 Mn in 2020, at a CAGR of 7.1% during 2021-2027. • The global Fine Chemicals market is anticipated to rise at a considerable rate during the forecast period, between 2022
Slide 22: Financial Overview
Financial Overview
Slide 23: Historical Income Statement
22 Historical Income Statement Income Statement (INR Mn) FY20 FY21 FY22 H1-FY23 Income from Operations 558 608 751 483 Total Expenses 464 447 588 388 EBITDA 94 161 163 95 EBITDA Margins (%) 16.85% 26.48% 21.70% 19.66% Finance Cost 8 7 5 1 Depreciation 27 28 33 16 Other Income 1 2 2 2 Profit before E
Slide 24: Balance Sheet
23 Balance Sheet EQUITIES & LIABILITIES (INR Mn) FY21 FY22 H1-FY23 ASSETS (INR Mn) FY21 FY22 H1-FY23 Shareholder Funds 522 599 659 Non Current Assets 352 351 363 (A) Equity Share Capital 61 123 123 (A) Fixed Assets - - - (B) Reserves & Surplus 461 476 536 (i) Tangible Assets 299 341 331 (ii) Capital
Slide 25: Financial Highlights
24 Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 751 26.48% 21.70% 19.08% 608 558 19.66% 483 16.85% 12.25% 12.42% 8.60% 116 60 92 94 161 163 95 48 FY20 FY21 FY22 H1-FY23 FY20 FY21 FY22 H1-FY23 FY20 FY21 FY22 H1-FY23 RoCE & RoE N
Slide 26: Capital Market Highlights
25 Capital Market Highlights Stock Market Performance (as on 30th September, 2022) 40% 20% 0% -20% -40% -60% 01-Oct 01-Nov 01-Dec 01-Jan 01-Feb 01-Mar 01-Apr 01-May 01-Jun 01-Jul 01-Aug 01-Sep Par Drugs Nifty 50 52 Price Data (30th September, 2022) INR Shareholding Pattern as on 30th September, 2022
Slide 27: Disclaimer
26 Disclaimer Par Drugs and Chemicals Limited: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection w
Slide 28: Thank You
Thank You
Par Drugs and Chemicals — Investor Presentation (November 2022) on 6ix